General MedicationsINTRAVENOUSGeneric
ZOMETA
ZOLEDRONIC ACID
Standard Dose
EQ 4MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Key Takeaways
- Primary indication: Review priority: STANDARD Marketing status: Discontinued
- Approval overview ZOMETA is listed in Drugs@FDA under application 021223 (NDA).
- Review priority: STANDARD Marketing status: Discontinued Active ingredient ZOLEDRONIC ACID Form and strength INJECTABLE;INTRAVENOUS - EQ 4MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NOVARTIS Submission history Latest submission status date: 2018-12-14 00:00:00.
Structured Monograph
Clinical summary
Approval overview ZOMETA is listed in Drugs@FDA under application 021223 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ZOLEDRONIC ACID Form and strength INJECTABLE;INTRAVENOUS - EQ 4MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NOVARTIS Submission history Latest submission status date: 2018-12-14 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.